We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Blood Vessels Grown in Lab to Treat Heart Disease

By LabMedica International staff writers
Posted on 02 Sep 2009
Although open-heart surgery is a frequent treatment for heart disease, it remains a very dangerous procedure. More...
New research from Israel has shown the potential for an injected protein to regrow blood vessels in the human heart--eliminating the need for risky surgery altogether.

In heart disease, either blood vessels are clogged or they die off, starving the heart of oxygen and leaving it highly susceptible to a cardiac attack. Dr. Britta Hardy and her research partner Prof. Alexander Battler, from Tel Aviv University's Sackler School of Medicine (Israel) have developed a protein-based injection that when delivered to muscles in the body, spurs the growth of tiny blood vessels. These new vessels in the heart could give millions of people worldwide a new lease on life.

An article on the procedure was published in the August 10, 2009, issue of the journal Biochemical Pharmacology. "The biotechnology behind our human-based protein therapy is very complicated, but the goal is simple and the solution is straightforward,” stated Dr. Hardy. "We intend to inject our drug locally to heal any oxygen-starved tissue. So far, in animal models, we have seen no side effects and no inflammation following our injection of the drug into the legs. The growth of new blood vessels happens within a few weeks, showing improved blood circulation.”

The protein solution can also be added as a coating to a stent. Currently, the implantation of a stent is accompanied by a high risk for blood clots, which necessitates the use of blood thinners. "We could coat a stent with our peptide, attracting endothelial stem cells to form a film on the surface of the stent,” Dr. Hardy explained. "These endothelial cells on the stent would eliminate the need for taking the blood thinners that prevent blood clots from forming.”

If investment goals are met, Dr. Hardy anticipates toxicity studies and phase I trials could be complete within two years. The research began with the hope of preventing leg amputations, positing that proteins from the human body could be used to trigger the growth of new blood vessels. Dr. Hardy started by studying a library of peptides and testing them in the laboratory. Dr. Hardy was able to validate initial results. She then took some of the isolated and synthesized peptides and tested them in diabetic mice whose legs were in the process of dying.

Although diabetes is known to decrease blood circulation, Dr. Hardy found that her therapy reversed the decrease. "Within a short time we saw the formation of capillaries and tiny blood vessels. After three weeks, they had grown and merged together with the rest of the circulatory system,” she commented. In mice with limited blood circulation, she was able to completely restore blood vessels and save their legs. The next step is examining the applicability of the research to cardiac patients.

A new therapy could be commercially available soon. Unlike studies for other drugs, clinical results with the blood vessels are nearly immediate. "It's pretty obvious if there is regrowth or not. Our technology promises to regrow blood vessels like a net, and a heart that grows more blood vessels becomes stronger. It's now imaginable that, in the distant future, peptide injections may be able to replace bypass surgeries,” Dr. Hardy concluded.

Related Links:

Tel Aviv University's Sackler School of Medicine




Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Molecular Diagnostics

view channel
Image: Spatial profiling of muscle-invasive bladder cancer reveals how distinct tumor cell states are organized within individual tumors (Image Credit: Shutterstock)

Spatial Map Guides Treatment Selection in Muscle-Invasive Bladder Cancer

Muscle-invasive bladder cancer is clinically heterogeneous, with patients often responding very differently to therapy. Existing biomarkers do not fully explain these disparities, limiting precision treatment... Read more

Microbiology

view channel
Image: Burkholderia pseudomallei is a soil-dwelling bacterium that causes melioidosis, a severe and potentially fatal infection that remains difficult to diagnose (Image Credit: Gavin Koh/Wikimedia Commons, CC BY-SA 4.0)

Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread

Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.